{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:34Z","timestamp":1791644614654,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41433-020-0876-2","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T13:05:09Z","timestamp":1588079109000},"page":"1797-1808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin"],"prefix":"10.1038","volume":"34","author":[{"given":"Tianchang","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/jop.2017.0095","volume":"34","author":"E Yildiz","year":"2018","unstructured":"Yildiz E, Yenerel NM, Turan-Yardimci A, Erkan M, Gunes P. Comparison of the clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis. J Ocul Pharm Ther. 2018;34:365\u201372.","journal-title":"J Ocul Pharm Ther"},{"key":"876_CR2","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","volume":"52","author":"KK Nichols","year":"2011","unstructured":"Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"876_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/BF00167872","volume":"229","author":"V Huber-Spitzy","year":"1991","unstructured":"Huber-Spitzy V, Baumgartner I, B\u00f6hler-Sommeregger K, Grabner G. Blepharitis-a diagnostic and therapeutic challenge. A report on consecutive cases. Graefes Arch Clin Exp Ophthalmol. 1991;229:224\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"876_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/cxo.12557","volume":"101","author":"O Balci","year":"2018","unstructured":"Balci O, Gulkilik G. Assessment of efficacy of topical azithromycin 1.5 per cent ophthalmic solution for the treatment of meibomian gland dysfunction. Clin Exp Optom. 2018;101:18\u201322.","journal-title":"Clin Exp Optom"},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/bjo.65.2.108","volume":"65","author":"AS Henriquez","year":"1981","unstructured":"Henriquez AS, Korb DR. Meibomian glands and contact lens wear. Br J Ophthalmol. 1981;65:108\u201311.","journal-title":"Br J Ophthalmol"},{"key":"876_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","volume":"25","author":"HD Perry","year":"2006","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171\u20135.","journal-title":"Cornea"},{"key":"876_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/jop.2006.22.47","volume":"22","author":"M Rubin","year":"2006","unstructured":"Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharm Ther. 2006;22:47\u201353.","journal-title":"J Ocul Pharm Ther"},{"key":"876_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/ceo.12666","volume":"44","author":"A AlHity","year":"2016","unstructured":"AlHity A, Lockington D. Oral azithromycin as the systemic treatment of choice in the treatment of meibomian gland disease. Clin Exp Ophthalmol. 2016;44:199\u2013201.","journal-title":"Clin Exp Ophthalmol"},{"key":"876_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1001\/archopht.116.12.1625","volume":"116","author":"KF Tabbara","year":"1998","unstructured":"Tabbara KF, al-Kharashi SA, al-Mansouri SM, al-Omar OM, Cooper H, el-Asrar AM, et al. Ocular levels of azithromycin. Arch Ophthalmol. 1998;116:1625\u20138.","journal-title":"Arch Ophthalmol"},{"key":"876_CR10","first-page":"1797","volume":"7","author":"J Qiao","year":"2013","unstructured":"Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797\u2013803.","journal-title":"Clin Ophthalmol"},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.exer.2010.05.014","volume":"91","author":"D Borchman","year":"2010","unstructured":"Borchman D, Yappert MC, Foulks GN. Changes in human meibum lipid with meibomian gland dysfunction using principal component analysis. Exp Eye Res. 2010;91:246\u201356.","journal-title":"Exp Eye Res"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1468-3083.2009.03132.x","volume":"23","author":"O Bakar","year":"2009","unstructured":"Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol. 2009;23:544\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1097\/ICO.0b013e318207fc42","volume":"30","author":"TZ Igami","year":"2011","unstructured":"Igami TZ, Holzchuh R, Osaki TH, Santo RM, Kara-Jose N, Hida RY. Oral azithromycin for treatment of posterior blepharitis. Cornea. 2011;30:1145\u20139.","journal-title":"Cornea"},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamaophthalmol.2013.5295","volume":"132","author":"JB Greene","year":"2014","unstructured":"Greene JB, Jeng BH, Fintelmann RE, Margolis TP. Oral azithromycin for the treatment of meibomitis. JAMA Ophthalmol. 2014;132:121\u20132.","journal-title":"JAMA Ophthalmol"},{"key":"876_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/ICO.0b013e3181ca38a0","volume":"29","author":"RM Haque","year":"2010","unstructured":"Haque RM, Torkildsen GL, Brubaker K, Zink RC, Kowalski RP, Mah FS, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871\u20137.","journal-title":"Cornea"},{"key":"876_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1444-0938.2010.00540.x","volume":"94","author":"DL Opitz","year":"2011","unstructured":"Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011;94:200\u20136.","journal-title":"Clin Exp Optom"},{"key":"876_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1869-5760-3-38","volume":"3","author":"S Doan","year":"2013","unstructured":"Doan S, Gabison E, Chiambaretta F, Touati M, Cochereau I. Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis. J Ophthalmic Inflamm Infec. 2013;3:38.","journal-title":"J Ophthalmic Inflamm Infec"},{"key":"876_CR18","first-page":"1501","volume":"55","author":"S Lazreg","year":"2014","unstructured":"Lazreg S. Role of Azithromycin in the treatment of children meibomian gland disease. Invest Ophthalmol Vis Sci. 2014;55:1501.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"876_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/09273948.2013.801991","volume":"21","author":"F Mantelli","year":"2013","unstructured":"Mantelli F, Di Zazzo A, Sacchetti M, Dianzani C, Lambiase A, Bonini S. Topical azithromycin as a novel treatment for ocular rosacea. Ocul Immunol Inflamm. 2013;21:371\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"876_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","volume":"32","author":"GN Foulks","year":"2013","unstructured":"Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32:44\u201353.","journal-title":"Cornea"},{"key":"876_CR21","first-page":"1016","volume":"9","author":"M Zandian","year":"2016","unstructured":"Zandian M, Rahimian N, Soheilifar S. Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis. Int J Ophthalmol. 2016;9:1016\u20139.","journal-title":"Int J Ophthalmol"},{"key":"876_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bjophthalmol-2014-305410","volume":"99","author":"MB Kashkouli","year":"2015","unstructured":"Kashkouli MB, Fazel AJ, Kiavash V, Nojomi M, Ghiasian L. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. Br J Ophthalmol. 2015;99:199\u2013204.","journal-title":"Br J Ophthalmol"},{"key":"876_CR23","first-page":"1481","volume":"55","author":"A Heitz","year":"2014","unstructured":"Heitz A, Arnaud S, Merklen C, Cribier B, Speeg-Schatz C, Bourcier T. Oral azithromycin versus doxycyclin for the treatment of moderate to severe meibomian gland dysfunction (MGD)\u2014a randomized prospective non-inferiority study. Invest Ophthalmol Vis Sci. 2014;55:1481.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"876_CR24","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","volume":"25","author":"J Luchs","year":"2008","unstructured":"Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25:858\u201370.","journal-title":"Adv Ther"},{"key":"876_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1590\/S0004-27492012000300006","volume":"75","author":"A Fadlallah","year":"2012","unstructured":"Fadlallah A, Rami HE, Fahd D, Dunia I, Bejjani R, Chlela E, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol. 2012;75:178\u201382.","journal-title":"Arq Bras Oftalmol"},{"key":"876_CR26","first-page":"47","volume":"55","author":"S Doan","year":"2014","unstructured":"Doan S, Baudouin C, Labetoulle M, Bourcier T, Hoffart L, Pisella PJ, et al. Efficacy and safety of azithromycin 1.5% eye drops (Azyter\u00ae) in patients with moderate to severe chronic blepharitis. Invest Ophthalmol Vis Sci. 2014;55:47.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"876_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1203\/PDR.0b013e318142582d","volume":"62","author":"ZH Aghai","year":"2007","unstructured":"Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62:483\u20138.","journal-title":"Pediatr Res"},{"key":"876_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/02713680701860499","volume":"33","author":"T Amar","year":"2008","unstructured":"Amar T, Caillaud T, Elena PP. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Curr Eye Res. 2008;33:149\u201358.","journal-title":"Curr Eye Res"},{"key":"876_CR29","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1167\/iovs.10-5658","volume":"52","author":"Z Sadrai","year":"2011","unstructured":"Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effects of topical azithromycin on corneal innate immune responses. Invest Ophthalmol Vis Sci. 2011;52:2525\u201331.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"876_CR30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/ICO.0000000000000351","volume":"34","author":"Y Liu","year":"2015","unstructured":"Liu Y, Kam WR, Ding J, Sullivan DA. Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation? Cornea. 2015;34:342\u20136.","journal-title":"Cornea"},{"key":"876_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/jop.2009.0026","volume":"25","author":"EK Akpek","year":"2009","unstructured":"Akpek EK, Vittitow J, Verhoeven RS, Brubaker K, Amar T, Powell KD, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharm Ther. 2009;25:433\u20139.","journal-title":"J Ocul Pharm Ther"},{"key":"876_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/112067210901900504","volume":"19","author":"A Iovieno","year":"2009","unstructured":"Iovieno A, Lambiase A, Micera A, Stampachiacchiere B, Sgrulletta R, Bonini S. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol. 2009;19:708\u201316.","journal-title":"Eur J Ophthalmol"},{"key":"876_CR33","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/bjo.68.8.524","volume":"68","author":"JM Dougherty","year":"1984","unstructured":"Dougherty JM, Mcculley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984;68:524\u20138.","journal-title":"Br J Ophthalmol"},{"key":"876_CR34","first-page":"314","volume":"105","author":"JP Mcculley","year":"1986","unstructured":"Mcculley JP, Dougherty JM. Bacterial aspects of chronic blepharitis. Trans Ophthalmol Soc UK. 1986;105:314\u20138.","journal-title":"Trans Ophthalmol Soc UK"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0876-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0876-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0876-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:48:16Z","timestamp":1721918896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0876-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-0876-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"assertion":[{"value":"28 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}